Volume : 7, Issue : 8, August - 2018

Reinvention of clinical use of Urine glucose test as a predictor of glucose lowering efficacy of SGLT2 inhibitor therapy as oral hypoglycemic agent in Type 2 diabetes mellitus.

Dr Kapil Deb Lahiri

Abstract :

<p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Backgrounds: </span></b><span style="font-size:12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">To reinvent the clinical use of Urine glucose test as a predictor of glucose<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">lowering efficacy of oral SGLT2 inhibitor therapy in Type 2 diabetes mellitus.<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Methods: </span></b><span style="font-size:12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Forty-six (Group A) new T2DM &amp; 42 (Group B) new T2DM with urine glucose test<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">results (+) &amp; (+++) respectively were given 2000 mg of metformin sustained release &amp; 10 mg<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">of dapagliflozin (SGLT2 inhibitor) per day who have baseline HbA1c of 7.8</span><!--[if gte msEquation 12]><m:oMath><span style=‘font-size:12.0pt;line-height:200%;font-family:"Times New Roman","serif"; mso-ascii-font-family:Calii;mso-ascii-theme-font:minor-latin‘><m:r><m:rPr><m:scr m:val="roman" /><m:sty m:val="p" /></m:rPr>±</m:r></span></m:oMath><![endif]--><!--[if !msEquation]--><span style="font-size:11.0pt;line-height:115%;font-family:&quot;Calii&quot;,&quot;sans-serif&quot;;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calii;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;position:relative;top:5.5pt;mso-text-raise:-5.5pt;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter" /> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0" /> <v:f eqn="sum @0 1 0" /> <v:f eqn="sum 0 0 @1" /> <v:f eqn="prod @2 1 2" /> <v:f eqn="prod @3 21600 pixelWidth" /> <v:f eqn="prod @3 21600 pixelHeight" /> <v:f eqn="sum @0 0 1" /> <v:f eqn="prod @6 1 2" /> <v:f eqn="prod @7 21600 pixelWidth" /> <v:f eqn="sum @8 21600 0" /> <v:f eqn="prod @7 21600 pixelHeight" /> <v:f eqn="sum @10 21600 0" /> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" /> <o:lock v:ext="edit" aspectratio="t" /> </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style=‘width:9pt; height:16.5pt‘> <v:imagedata src="file:///C:UsersWWJ-09AppDataLocalTempmsohtmlclip11clip_image001.png" o:title="" chromakey="white" /> </v:shape><![endif]--><!--[if !vml]--><img width="12" height="22" src="file:///C:/Users/WWJ-09/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" v:shapes="_x0000_i1025" alt="" /><!--[endif]--></span><!--[endif]--><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;mso-fareast-font-family:&#10;&quot;Times New Roman&quot;;mso-fareast-theme-font:minor-fareast"><span style="mso-spacerun:yes">&nbsp;</span>0.3% &amp;</span><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">7.9</span><!--[if gte msEquation 12]><m:oMath><span style=‘font-size:12.0pt;line-height:200%;font-family:"Times New Roman","serif"; mso-ascii-font-family:Calii;mso-ascii-theme-font:minor-latin‘><m:r><m:rPr><m:scr m:val="roman" /><m:sty m:val="p" /></m:rPr>±</m:r></span></m:oMath><![endif]--><!--[if !msEquation]--><span style="font-size:11.0pt;line-height:115%;font-family:&quot;Calii&quot;,&quot;sans-serif&quot;;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calii;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;position:relative;top:5.5pt;mso-text-raise:-5.5pt;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><!--[if gte vml 1]><v:shape id="_x0000_i1025" type="#_x0000_t75" style=‘width:9pt;height:16.5pt‘> <v:imagedata src="file:///C:UsersWWJ-09AppDataLocalTempmsohtmlclip11clip_image001.png" o:title="" chromakey="white" /> </v:shape><![endif]--><!--[if !vml]--><img width="12" height="22" src="file:///C:/Users/WWJ-09/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" v:shapes="_x0000_i1025" alt="" /><!--[endif]--></span><!--[endif]--><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;mso-fareast-font-family:&#10;&quot;Times New Roman&quot;;mso-fareast-theme-font:minor-fareast"><span style="mso-spacerun:yes">&nbsp;</span>0.3%</span><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">respectively and fasting plasma glucose of 180</span><!--[if gte msEquation 12]><m:oMath><span style=‘font-size:12.0pt;line-height:200%;font-family:"Times New Roman","serif"; mso-ascii-font-family:Calii;mso-ascii-theme-font:minor-latin‘><m:r><m:rPr><m:scr m:val="roman" /><m:sty m:val="p" /></m:rPr>±</m:r></span></m:oMath><![endif]--><!--[if !msEquation]--><span style="font-size:11.0pt;line-height:115%;font-family:&quot;Calii&quot;,&quot;sans-serif&quot;;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calii;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;position:relative;top:5.5pt;mso-text-raise:-5.5pt;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><!--[if gte vml 1]><v:shape id="_x0000_i1025" type="#_x0000_t75" style=‘width:9pt;height:16.5pt‘> <v:imagedata src="file:///C:UsersWWJ-09AppDataLocalTempmsohtmlclip11clip_image001.png" o:title="" chromakey="white" /> </v:shape><![endif]--><!--[if !vml]--><img width="12" height="22" src="file:///C:/Users/WWJ-09/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" v:shapes="_x0000_i1025" alt="" /><!--[endif]--></span><!--[endif]--><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">15mg/dl &amp; 184</span><!--[if gte msEquation 12]><m:oMath><span style=‘font-size:12.0pt;line-height:200%;font-family:"Times New Roman","serif"; mso-ascii-font-family:Calii;mso-ascii-theme-font:minor-latin‘><m:r><m:rPr><m:scr m:val="roman" /><m:sty m:val="p" /></m:rPr>±</m:r></span></m:oMath><![endif]--><!--[if !msEquation]--><span style="font-size:11.0pt;line-height:115%;font-family:&quot;Calii&quot;,&quot;sans-serif&quot;;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calii;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;position:relative;top:5.5pt;mso-text-raise:-5.5pt;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><!--[if gte vml 1]><v:shape id="_x0000_i1025" type="#_x0000_t75" style=‘width:9pt;height:16.5pt‘> <v:imagedata src="file:///C:UsersWWJ-09AppDataLocalTempmsohtmlclip11clip_image001.png" o:title="" chromakey="white" /> </v:shape><![endif]--><!--[if !vml]--><img width="12" height="22" src="file:///C:/Users/WWJ-09/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" v:shapes="_x0000_i1025" alt="" /><!--[endif]--></span><!--[endif]--><span style="font-size:12.0pt;&#10;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">14mg/dl respectively. Theywere followed up at an interval of three months up to six months with HbA1c, fasting plasmaglucose &amp; urine glucose test.<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Results: </span></b><span style="font-size:12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Better HbA1c and fasting plasma glucose reductionwas seen in Group A than Group B patients.<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;line-height:&#10;200%;mso-layout-grid-align:none;text-autospace:none"><b><span style="font-size:&#10;12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">Conclusion: </span></b><span style="font-size:12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">urine glucose testing can predict the glucose lowering efficacy of oralSGLT2 inhibitor therapy in Type 2 diabetes mellitus.<o:p></o:p></span></p>